Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II panitumumab monotherapy in pretreated advanced well-differentiated neuroendocrine tumor
2012-004539-22Phase 2Completed
- Sponsor
- ITMO University
- Start
- Jan 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in apudoma (NET), sponsored by ITMO University. Primary endpoint: Non-progression rate at 6 months. Started Jan 2013; status: completed.
02
Drugs
panitumumab
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on 2012-004539-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004539-22.